Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C6H11BrN2O2 |
| Molecular Weight | 223.068 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(Br)C(=O)NC(N)=O
InChI
InChIKey=CMCCHHWTTBEZNM-UHFFFAOYSA-N
InChI=1S/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/25732089Curator's Comment: description was created based on several sources, including
https://www.ipi-singapore.org/technology-offers/bromvalerylurea-skin-inflammation
Sources: http://www.ncbi.nlm.nih.gov/pubmed/25732089
Curator's Comment: description was created based on several sources, including
https://www.ipi-singapore.org/technology-offers/bromvalerylurea-skin-inflammation
Bromisoval (INN; aka bromvalerylurea) is a hypnotic and sedative compound of the bromoureide group discovered by Knoll in 1907 and patented in 1909. It is marketed over the counter in Asia under various trade names (such as Brovarin) usually in combination with non-steroidal anti-inflammatory drugs. Chronic use of bromisoval has been associated with bromine poisoning. Bromovisal can be prepared by bromination of isovaleric acid by the Hell-Volhard-Zelinsky reaction followed by reaction with urea. Bromvalerylurea (BU) can suppress expression of many kinds of pro- and anti-inflammatory mediators in LPS- or interferon-γ activated alveolar and peritoneal macrophages. Bromisoval was found to ameliorate sepsis in rats. It also prevents elevated serum-IL-6 level as well as IL-6 mRNA expression in septic rats. Bromisoval was also found useful for inflammatory skin disorders. The compound is able to suppress the TLR ligands-induced proinflammatory response similar to the steroid DEX without the side effects often associated with the steroid usage.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Bromisoval Approved UseFor treatment of insomnia, agitation, chorea, whooping cough |
|||
| Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/25732089 |
Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12851661/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
80.07 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17442639/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMENHYDRINATE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
47.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
38.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, sublingual dose: 50 mg route of administration: Sublingual experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
155.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12851661/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
788.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17442639/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMENHYDRINATE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
528 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
270 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
221 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, sublingual dose: 50 mg route of administration: Sublingual experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12851661/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17442639/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMENHYDRINATE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2328304/ |
50 mg single, sublingual dose: 50 mg route of administration: Sublingual experiment type: SINGLE co-administered: |
DIPHENHYDRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/25732089
for rats: bromvalerylurea (BROMISOVAL) was subcutaneously administered twice per day
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
N05CM03
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
||
|
WHO-VATC |
QN05CM03
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D001968
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
DTXSID2040656
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
469GW8R486
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
2447
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
100000088677
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
DB13370
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
207-825-7
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
Bromisoval
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
31304
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL1515611
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
66101-52-8
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
SUPERSEDED | |||
|
496-67-3
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
m2674
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
12622-72-9
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
SUPERSEDED | |||
|
77043
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
3038
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
C76935
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
SUB05916MIG
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY | |||
|
1231
Created by
admin on Mon Mar 31 17:54:35 GMT 2025 , Edited by admin on Mon Mar 31 17:54:35 GMT 2025
|
PRIMARY |
ACTIVE MOIETY